Security
Lipella Pharmaceuticals Inc. Common Stock · LIPO
LIPONASDAQCommon stockHistorical · closed Jun 18, 2025CIK 1347242Updated Oct 27, 2026
LIPO price & chart
This listing closed Jun 18, 2025. Live provider charts are shown only for current listings.
Current security: LIPO
About the company
Lipella Pharmaceuticals is a clinical-stage biotechnology company focused on developing new drugs by reformulating active agents in existing generic drugs and optimizing these reformulations for new applications. Lipella targets diseases with significant unmet needs, where no approved drug therapies currently exist. The company completed its initial public offering in 2022. Learn more at lipella.com and follow us on X and LinkedIn.
In the news
No coverage from other publishers is available.
Recent filings
Bankruptcy or Receivership
Items 1.03, 9.01
Bankruptcy or Receivership
Items 1.03
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements
Items 5.02
10-Q filing
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements
Items 5.02
Show 5 more recent filings
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements
Items 5.02
25-NSE - filed by Nasdaq Stock Market LLC regarding LIPELLA PHARMACEUTICALS INC.
Regulation FD Disclosure · Other Events
Items 7.01, 8.01, 9.01
10-Q filing
Regulation FD Disclosure · Other Events
Items 7.01, 8.01, 9.01
Financials
FY 2024 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q3 2023 | Q2 2025 | Q2 2024 | Q2 2023 | Q1 2025 | Q1 2024 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 2,349,810Source | 2,160,105Source | 2,840,945Source | 3,720,206Source | 2,184,112Source | 3,489,536Source | 4,856,051Source | 3,137,157Source | 2,673,870Source | 3,577,174Source | 5,950,110Source | 2,012,889Source |
| Property, Plant and Equipment, NetUSD | 7,699Source | 10,585Source | 13,472Source | 8,420Source | 11,307Source | — | 9,142Source | 12,029Source | 9,864Source | 12,750Source | — | — |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 1,855,771Source | 1,353,734Source | 2,409,847Source | 2,781,828Source | 1,186,506Source | 3,113,644Source | 4,225,012Source | 2,105,299Source | 2,184,863Source | 3,293,738Source | 5,121,743Source | 1,413,828Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | — | 31,079Source | 53,140Source | — | 35,332Source | 28,044Source | — | 68,934Source | 84,713Source | 32,286Source | 113,655Source | — |
| Assets, CurrentUSD | 2,079,288Source | 2,079,965Source | 2,671,067Source | 3,437,246Source | 2,080,827Source | 3,366,990Source | 4,823,337Source | 3,011,090Source | 2,617,252Source | 3,429,280Source | 5,799,289Source | 1,808,089Source |
| Operating Lease, Right-of-Use AssetUSD | 262,823Source | 69,555Source | 156,406Source | 274,539Source | 91,978Source | 122,546Source | 23,572Source | 114,038Source | 46,754Source | 135,144Source | 150,821Source | 204,800Source |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 862,215Source | 701,186Source | 619,214Source | 978,534Source | 480,313Source | 364,194Source | 776,847Source | 575,878Source | 754,417Source | 432,726Source | 1,274,514Source | 589,337Source |
| Stockholders’ equity: | ||||||||||||
| Preferred Stock, Value, IssuedUSD | — | — | — | — | — | — | — | — | 33Source | — | — | 159Source |
| Common Stock, Value, IssuedUSD | 462Source | 109Source | 580Source | 446Source | 761Source | 574Source | 254Source | 704Source | 121Source | 605Source | 574Source | 387Source |
| Additional Paid in CapitalUSD | 20,715,326Source | 15,357,244Source | 11,856,110Source | 20,715,326Source | 14,156,836Source | 11,436,157Source | 20,725,522Source | 14,076,227Source | 17,259,406Source | 13,467,686Source | 10,379,900Source | 4,530,193Source |
| Retained Earnings (Accumulated Deficit)USD | -19,228,194Source | -13,898,435Source | -9,634,959Source | -17,974,116Source | -12,453,799Source | -8,311,389Source | -16,646,630Source | -11,515,652Source | -15,340,107Source | -10,323,843Source | -5,704,878Source | -3,107,187Source |
| Stockholders' Equity Attributable to ParentUSD | 1,487,595Source | 1,458,918Source | 2,221,731Source | 2,741,672Source | 1,703,798Source | 3,125,342Source | 4,079,204Source | 2,561,278Source | 1,919,453Source | 3,144,448Source | 4,675,596Source | 1,423,552Source |
| Liabilities and EquityUSD | 2,349,810Source | 2,160,105Source | 2,840,945Source | 3,720,206Source | 2,184,111Source | 3,489,536Source | 4,856,051Source | 3,137,157Source | 2,673,870Source | 3,577,174Source | 5,950,110Source | 2,012,889Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 642,399Source | 701,186Source | 548,730Source | 746,898Source | 480,313Source | 298,804Source | 776,846Source | 551,881Source | 754,417Source | 385,355Source | 1,178,256Source | 340,625Source |
| Operating Lease, Liability, CurrentUSD | 44,267Source | 70,830Source | 87,272Source | 42,903Source | 93,679Source | 60,788Source | 23,997Source | 91,705Source | 47,605Source | 89,223Source | 58,262Source | 39,598Source |
| Accounts Payable, CurrentUSD | 462,892Source | 459,453Source | 303,052Source | 608,110Source | 178,361Source | 22,057Source | 392,115Source | 293,835Source | 388,191Source | 138,016Source | 384,357Source | 46,900Source |
| Operating Lease, Liability, NoncurrentUSD | 219,816Source | — | 70,484Source | 231,636Source | — | 65,390Source | — | 23,997Source | — | 47,371Source | 96,258Source | 168,363Source |
| Other Liabilities, NoncurrentUSD | — | — | — | — | — | — | — | — | — | — | — | 50,000Source |
| Additional Financial Items | ||||||||||||
| Accrued Liabilities, CurrentUSD | 34,938Source | 89,773Source | 76,075Source | 15,087Source | 126,999Source | 138,704Source | 258,310Source | 84,929Source | 237,886Source | 77,280Source | 389,209Source | 151,521Source |
| Short-term InvestmentsUSD | — | — | — | — | — | — | — | — | — | — | — | 300,546Source |
cash flow · annual statements
| Line item | Q4 2024 | Q4 2023 | Q3 2025 | Q3 2024 | Q2 2025 | Q2 2024 | Q1 2025 | Q1 2024 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Depreciation, Depletion and AmortizationUSD | — | — | — | — | — | — | 722Source | 721Source | 2,886Source | 1,685Source | — | — |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts PayableUSD | — | — | — | — | — | — | 3,925Source | 155,819Source | 250,175Source | -246,341Source | 337,456Source | 22,360Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -1,426,126Source | -1,388,438Source | -3,950,747Source | -3,150,172Source | -1,831,161Source | -989,271Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | — | — | — | -14,434Source | 300,546Source | -300,546Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | — | — | — | 14,434Source | — | — |
| Cash flows from financing activities: | ||||||||||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | 3,466,275Source | 200,000Source | 2,841,872Source | 1,336,601Source | 5,238,530Source | 2,096,909Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | 1,855,770Source | 1,353,736Source | 2,781,827Source | 1,186,507Source | 4,225,012Source | 2,105,299Source | 2,184,863Source | 3,293,738Source | 5,121,743Source | 1,413,828Source |
| Supplemental disclosure of cash flow information: | ||||||||||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | — | — | — | — | — | — | 4,152Source | 6,234Source | 11,908Source | — | — | — |
| Income Taxes Paid, NetUSD | — | — | — | — | — | — | — | 6,234Source | — | -11,358Source | — | — |
| Additional Financial Items | ||||||||||||
| DepreciationUSD | — | — | — | — | — | — | — | — | 2,886Source | 1,685Source | 0Source | 0Source |
| General and Administrative ExpenseUSD | — | — | 553,299Source | 493,102Source | 651,721Source | 427,062Source | 463,736Source | 520,926Source | 2,003,712Source | 2,156,734Source | 226,192Source | 718,384Source |
| Investment Income, InterestUSD | — | — | 20,194Source | 14,778Source | 29,089Source | 14,043Source | 21,298Source | 25,837Source | 64,278Source | 137,836Source | 1,678Source | 104Source |
| Marketable Securities, Unrealized Gain (Loss)USD | — | — | — | — | — | — | — | — | — | — | — | -29Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -1,254,078Source | -1,444,637Source | -1,327,486Source | -938,146Source | -1,306,523Source | -1,191,809Source | -5,016,264Source | -4,618,965Source | -2,597,692Source | -1,865,473Source |
| Nonoperating Income (Expense)USD | — | — | 20,194Source | 14,778Source | 29,089Source | 14,043Source | 21,298Source | 25,837Source | 64,278Source | 126,988Source | -7,979Source | 50,355Source |
| Operating Costs and ExpensesUSD | — | — | 1,274,272Source | 1,539,795Source | 1,443,302Source | 1,088,620Source | 1,457,211Source | 1,363,526Source | 5,616,899Source | 5,195,570Source | 2,773,869Source | 2,175,175Source |
| Operating Lease, ExpenseUSD | — | — | 16,304Source | 23,834Source | 23,834Source | 23,834Source | 23,608Source | 24,438Source | 96,930Source | 77,763Source | 64,823Source | 65,585Source |
| Proceeds from Issuance of Common StockUSD | — | — | — | — | — | — | 3,466,275Source | 200,000Source | — | — | 4,963,530Source | 2,096,909Source |
| Proceeds from Stock Options ExercisedUSD | — | — | — | — | — | — | — | — | — | 121,200Source | — | — |
income statement · annual statements
| Line item | Q4 2024 | Q4 2023 | Q3 2025 | Q3 2024 | Q2 2025 | Q2 2024 | Q1 2025 | Q1 2024 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total RevenueUSD | — | — | — | 80,380Source | 86,727Source | 136,431Source | 129,390Source | 145,880Source | 536,357Source | 449,617Source | 184,156Source | 259,347Source |
| Operating Income (Loss)USD | — | — | -1,274,272Source | -1,459,415Source | -1,356,575Source | -952,189Source | -1,327,821Source | -1,217,646Source | -5,080,542Source | -4,745,953Source | -2,589,713Source | -1,915,828Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | — | — | -1,254,078Source | -1,444,637Source | -1,327,486Source | -938,146Source | -1,306,523Source | -1,191,809Source | -5,016,264Source | -4,618,965Source | -2,597,692Source | -1,865,473Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -1,254,078Source | -1,444,637Source | -1,327,486Source | -938,146Source | -1,306,523Source | -1,191,809Source | -5,016,264Source | -4,618,965Source | -2,597,692Source | -1,865,473Source |
| Earnings Per Share, BasicUSD per share | — | — | -0.28Source | -1.29Source | -0.31Source | -0.99Source | -0.64Source | -1.31Source | -4.79Source | -0.77Source | -0.64Source | -0.55Source |
| Earnings Per Share, DilutedUSD per share | — | — | -0.28Source | -1.29Source | -0.31Source | -0.99Source | -0.64Source | -1.31Source | -4.79Source | -0.77Source | -0.64Source | -0.55Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 4,549,120Source | 1,119,129Source | 4,305,243Source | 950,669Source | 2,056,804Source | 911,515Source | 1,048,185Source | 6,003,074Source | 4,060,624Source | 3,408,051Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 4,549,120Source | 1,119,129Source | 4,305,243Source | 950,669Source | 2,056,804Source | 911,515Source | 1,048,185Source | 6,003,074Source | 4,060,624Source | 3,408,051Source |
| Additional Financial Items | ||||||||||||
| General and Administrative ExpenseUSD | — | — | 553,299Source | 493,102Source | 651,721Source | 427,062Source | 463,736Source | 520,926Source | 2,003,712Source | 2,156,734Source | 226,192Source | 718,384Source |
| Interest ExpenseUSD | — | — | — | — | — | — | — | — | — | 10,848Source | 9,612Source | 6,834Source |
| Investment Income, InterestUSD | — | — | 20,194Source | 14,778Source | 29,089Source | 14,043Source | 21,298Source | 25,837Source | 64,278Source | 137,836Source | 1,678Source | 104Source |
| Nonoperating Income (Expense)USD | — | — | 20,194Source | 14,778Source | 29,089Source | 14,043Source | 21,298Source | 25,837Source | 64,278Source | 126,988Source | -7,979Source | 50,355Source |
| Operating Costs and ExpensesUSD | — | — | 1,274,272Source | 1,539,795Source | 1,443,302Source | 1,088,620Source | 1,457,211Source | 1,363,526Source | 5,616,899Source | 5,195,570Source | 2,773,869Source | 2,175,175Source |
| Operating Lease, ExpenseUSD | — | — | 16,304Source | 23,834Source | 23,834Source | 23,834Source | 23,608Source | 24,438Source | 96,930Source | 77,763Source | 64,823Source | 65,585Source |
| Other IncomeUSD | — | — | — | — | — | — | — | — | — | — | -45Source | 57,085Source |
| Research and Development ExpenseUSD | — | — | 720,973Source | 1,046,693Source | 791,581Source | 661,558Source | 993,475Source | 842,600Source | 3,613,187Source | 3,038,836Source | 2,547,677Source | 1,456,791Source |
Filing attachments
g085465_ex99-1.htm · 8-K · 2026-03-31
EX-99.1 2 g085465_ex99-1.htm PRESS RELEASE Exhibit 99.1 Press Release FOR IMMEDIATE RELEASE Lipella Pharmaceuticals Inc. Files Voluntary Petitions for Relief Under Chapter 11 [Pittsburgh, Pennsylvania] - [March 30, 2026] - Lipella Pharmaceuticals Inc. (“Lipella” or the “Company”), a clinical-stage biotechnology company, announced today that it filed a voluntary petition for relief under Chapter 11 of the U.S. Bankruptcy Code in the United States Bankruptcy Court for the Western District…
Read attachment ↗g084955_ex99-1.htm · 8-K · 2025-09-18
EX-99.1 2 g084955_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Lipella Pharmaceuticals Announces Positive Final Results from Phase 2a Study of LP-10 in Oral Lichen Planus All 27 patients completed treatment with no serious adverse events, underscoring a favorable safety profile Statistically significant improvements achieved across all efficacy endpoints at the 4-week timepoint Preparing to initiate a pivotal Phase 2b study to advance LP-10 toward registration PITTSBURGH, Septembe…
Read attachment ↗g084955_ex99-2.htm · 8-K · 2025-09-18
EX-99.2 3 g084955_ex99-2.htm EXHIBIT 99.2 Exhibit 99.2 1 lipellapharmaceuticals.com A Clinical Stage Biotechnology Company Transforming Care with Innovative Mucosal Delivery Solutions Corporate Presentation September 2025 2 Disclaimers The information in this presentation is being provided so you can familiarize yourself with Lipella Pharmaceuticals Inc. (“ Lipella,” the “Company,” “we,” “us,” or “our”) during this informational meeting. We request that you keep any information we provide …
Read attachment ↗g084855_ex99-1.htm · 8-K · 2025-06-25
EX-99.1 2 g084855_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 LIPELLA PHARMACEUTICALS INC. LETTER FROM THE CEO Dear Fellow Stockholders: Over the past few days, I have received many calls, texts, and emails asking questions about our status. In a genuine effort to keep stockholders up to date, I have reproduced the majority of questions received, along with responses so that all stockholders can understand where the Company currently stands and its current prospects and plans. 1. Why was Lipel…
Read attachment ↗g084855_ex99-2.htm · 8-K · 2025-06-25
EX-99.2 3 g084855_ex99-2.htm EXHIBIT 99.2 Exhibit 99.2 Lipella Pharmaceuticals Issues Letter from the CEO to Stockholders Following Nasdaq Delisting PITTSBURGH, PA - June 25, 2025 - Lipella Pharmaceuticals Inc. (OTC: LIPO) (“Lipella” or the “Company”), a clinical-stage biotechnology company focused on developing therapies for diseases with significant unmet need, today issued a letter from Chief Executive Officer Jonathan Kaufman to stockholders. The letter provides detailed responses to f…
Read attachment ↗g084852_ex99-1.htm · 8-K · 2025-06-20
EX-99.1 2 g084852_ex99-1.htm PRESS RELEASE Exhibit 99.1 Lipella Pharmaceuticals Announces Delisting from Nasdaq Capital Market PITTSBURGH, PA - June 20, 2025 - Lipella Pharmaceuticals Inc. (“Lipella” or the “Company”), a clinical-stage biotechnology company focused on developing therapies for diseases with significant unmet needs, today announced that the Nasdaq Hearings Panel has determined to delist the Company’s common stock from The Nasdaq Capital Market. Trading in the common stock wa…
Read attachment ↗